- Home
- NAC vs OCS Comparison
NAC vs OCS Comparison
Compare NAC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAC | OCS |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | France | Switzerland |
| Employees | N/A | 60 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | NAC | OCS |
|---|---|---|
| Price | $11.72 | $11.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 335.6K | ★ 358.5K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $466.06 |
| Revenue Next Year | N/A | $479.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.94 | $10.52 |
| 52 Week High | $12.25 | $34.48 |
Technical Indicators
Market Signals| Indicator | NAC | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 26.23 | 30.55 |
| Support Level | $11.64 | $10.52 |
| Resistance Level | $12.04 | $21.79 |
| Average True Range (ATR) | 0.08 | 0.68 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 0.05 | 8.97 |
Price Performance
Historical ComparisonAbout NAC Nuveen California Quality Municipal Income Fund
Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.